Bio-Techne Navigates Headwinds with 5% Organic Growth, Strategic Divestitures

Ticker: TECH · Form: DEF 14A · Filed: Sep 19, 2025 · CIK: 842023

Bio-Techne Corp DEF 14A Filing Summary
FieldDetail
CompanyBio-Techne Corp (TECH)
Form TypeDEF 14A
Filed DateSep 19, 2025
Risk Levelmedium
Pages14
Reading Time17 min
Key Dollar Amounts$326M, $1.2 billion, $0, $1.92, $326 million
Sentimentmixed

Sentiment: mixed

Topics: Biotech, Life Sciences, Diagnostics, Corporate Governance, Shareholder Engagement, Executive Compensation, Strategic Divestitures

Related Tickers: TECH

TL;DR

**TECH is shedding non-core assets and doubling down on high-growth, high-margin innovation, making it a solid long-term play despite a GAAP EPS dip.**

AI Summary

BIO-TECHNE Corp (TECH) achieved $1.2196 billion in total revenue for fiscal year 2025, demonstrating 5% organic growth despite a dynamic operating environment marked by biotech funding constraints and macroeconomic challenges in China. The company maintained a strong adjusted operating margin of 31.6%, though slightly down from 32.1% in fiscal year 2024 due to incentive compensation accruals and unfavorable product mix. GAAP earnings per diluted share were $0.46, a significant decrease from $1.05 in fiscal year 2024, while adjusted EPS rose to $1.92 from $1.77. TECH returned $326 million to shareholders through $50 million in dividends and $276 million in share buybacks. Strategic initiatives included divesting the Fetal Bovine Serum (FBS) business and Exosome Diagnostics to sharpen focus on high-margin products and growth pillars like cell therapy workflow solutions and proteomic analytical tools. The company also expanded its portfolio with over 500 new products and established a distribution agreement with Spear Bio for ultrasensitive assays.

Why It Matters

BIO-TECHNE's strategic divestitures of the FBS business and Exosome Diagnostics signal a clear pivot towards higher-margin, innovative product lines, which could enhance long-term profitability and investor confidence. The 5% organic growth and $1.2196 billion in revenue, despite industry headwinds, demonstrate resilience and effective execution, positioning TECH favorably against competitors facing similar market pressures. For employees, this sharpened focus could mean increased investment in core growth areas, fostering innovation and career development. Customers will benefit from an expanded portfolio of over 500 new products and strategic partnerships like the one with Spear Bio, offering advanced tools for scientific and medical research.

Risk Assessment

Risk Level: medium — While BIO-TECHNE achieved 5% organic growth and $1.2196 billion in revenue, GAAP earnings per diluted share significantly decreased to $0.46 from $1.05 in fiscal year 2024. This substantial drop in GAAP EPS, despite positive adjusted EPS growth, indicates underlying profitability challenges or one-time charges that warrant closer scrutiny, posing a medium risk to investors.

Analyst Insight

Investors should closely monitor BIO-TECHNE's GAAP earnings in future filings to ensure the strategic divestitures translate into improved bottom-line profitability. The company's commitment to a 'bench test' for new enterprise performance goals in FY26 suggests a proactive approach to compensation and strategy, which could signal future operational efficiencies.

Financial Highlights

debt To Equity
X.X
revenue
$1.2196B
operating Margin
31.6%
total Assets
$X
total Debt
$X
net Income
$X
eps
$0.46
gross Margin
X%
cash Position
$X
revenue Growth
+5%

Executive Compensation

NameTitleTotal Compensation
Not DisclosedExecutive Officer$X

Key Numbers

  • $1.2196B — Total Company Revenue (Achieved in fiscal year 2025, demonstrating 5% organic growth.)
  • 5% — Organic Growth (Achieved for the fiscal year 2025 despite a dynamic operating environment.)
  • 31.6% — Adjusted Operating Margin (Achieved in fiscal year 2025, compared to 32.1% in the prior year.)
  • $0.46 — GAAP Earnings Per Diluted Share (Reported in fiscal year 2025, a decrease from $1.05 in fiscal year 2024.)
  • $1.92 — Adjusted EPS (Reported in fiscal year 2025, an increase from $1.77 in fiscal year 2024.)
  • $326M — Capital Returned to Shareholders (Comprised of $50 million in dividends and $276 million in share buybacks.)
  • 500+ — New Products (Introduced in fiscal year 2025, broadening the unique portfolio.)
  • 100% — Cap on rTSR metric (Implemented for 3-year performance-based grants where TSR is negative, effective for fiscal 2025.)
  • 80% — Shareholders Engaged (Management met with representatives of 80% of shareholders during fiscal 2025.)
  • 9 — Board Members (Proposed number of members for the Board of Directors.)

Key Players & Entities

  • BIO-TECHNE Corp (company) — Registrant
  • Kim Kelderman (person) — President and Chief Executive Officer
  • KPMG, LLP (company) — Independent Registered Public Accounting Firm
  • Dr. Amy Herr (person) — New Board Director
  • Dr. Roeland Nusse (person) — Retiring Board Director
  • Rupert Vessey (person) — Chair of the Science and Technology Committee
  • Dr. Judith Klimovsky (person) — Member of the Nominations and Governance Committee
  • Spear Bio (company) — Strategic partner for ultrasensitive assays
  • Mdxhealth SA (company) — Acquirer of Exosome Diagnostics Inc. business
  • Shane V. Bohnen (person) — Senior Vice President, General Counsel and Corporate Secretary

FAQ

What were BIO-TECHNE's key financial results for fiscal year 2025?

BIO-TECHNE achieved $1.2196 billion in total revenue, representing 5% organic growth. GAAP earnings per diluted share were $0.46, while adjusted EPS reached $1.92. The adjusted operating margin stood at 31.6%.

How did BIO-TECHNE address shareholder feedback regarding executive compensation in fiscal year 2025?

In response to shareholder feedback, BIO-TECHNE's Compensation Committee implemented a 100% cap on the rTSR metric for 3-year performance-based grants when TSR is negative. They also designed a one-year 'bench test' for enterprise-wide performance goals to evaluate potential new metrics for fiscal 2027 compensation plans.

What strategic changes did BIO-TECHNE make to its business portfolio in fiscal year 2025?

BIO-TECHNE completed the divestiture of its Fetal Bovine Serum (FBS) business and agreed to sell Exosome Diagnostics Inc. to Mdxhealth SA. These actions were taken to sharpen the company's strategic focus on innovative, high-margin products within its four growth pillars.

What is BIO-TECHNE's approach to corporate sustainability?

BIO-TECHNE implemented a carbon accounting system, expanded data collection to include Scope 3 emissions, and committed to setting a science-based target by September 2026. The company also maintained its bronze medal with EcoVadis and expanded its scope of assessments to include CDP.

Who are the new and retiring members of BIO-TECHNE's Board of Directors?

Dr. Amy Herr was appointed to the Board of Directors on February 1, 2025, and Dr. Roeland Nusse retired after 15 years of service. Rupert Vessey was appointed Chair of the Science and Technology Committee, and Dr. Judith Klimovsky joined the Nominations and Governance Committee.

What are the key proposals for shareholders to vote on at BIO-TECHNE's 2025 Annual Meeting?

Shareholders will vote on setting the Board of Directors at nine members, electing the nine nominated directors, approving executive officer compensation on an advisory basis, and ratifying KPMG, LLP as the independent registered public accounting firm for fiscal year 2026.

How does BIO-TECHNE ensure Board refreshment and diversity?

BIO-TECHNE has a policy requiring directors to retire at age 75, subject to waiver. The company also emphasizes a regular Board refreshment process, with 44% of independent directors new since 2019, and its Principles of Corporate Governance codify a commitment to a diverse range of qualified professionals.

What is BIO-TECHNE's stance on shareholder engagement?

BIO-TECHNE values shareholder perspectives, with management meeting frequently with key shareholders to discuss financial performance, strategies, executive compensation, governance, and ESG issues. In fiscal 2025, management met with representatives of 80% of its shareholders.

How does BIO-TECHNE manage enterprise risks, including cybersecurity and AI?

The Board of Directors provides oversight of material enterprise risks, with management giving periodic reports on cybersecurity, privacy, environmental, and compliance risks. The Board formally assigned oversight of AI tools' applications, use, and risks to the Science and Technology Committee.

What new products and partnerships did BIO-TECHNE introduce in fiscal year 2025?

BIO-TECHNE expanded its portfolio with over 500 new products, including the Simple Western instrument Leo and the QuantideX ESR1 exoMutation Kit. The company also established a strategic distribution agreement with Spear Bio for next-generation ultrasensitive immunoassays, focusing initially on Alzheimer's disease research biomarkers.

Risk Factors

  • Executive Compensation Alignment [medium — financial]: The Compensation Committee refined the relative total shareholder return (rTSR) metric, making up 25% of the three-year performance-vesting incentive. A 100% cap was imposed on rTSR payout if Bio-Techne's TSR is negative over the three-year period, aiming for greater alignment with shareholder experience.
  • Product Mix Impact on Margins [medium — operational]: The adjusted operating margin slightly decreased to 31.6% in fiscal year 2025 from 32.1% in fiscal year 2024. This was attributed to incentive compensation accruals and an unfavorable product mix, indicating potential challenges in optimizing profitability across the product portfolio.
  • Biotech Funding Constraints [medium — market]: The company experienced 5% organic growth in fiscal year 2025 despite a dynamic operating environment marked by biotech funding constraints. This suggests that external market conditions are impacting the company's ability to achieve higher growth rates.
  • Macroeconomic Challenges in China [medium — market]: The dynamic operating environment also included macroeconomic challenges in China, which likely impacted revenue generation and growth in that specific region. The DEF 14A does not provide specific revenue figures for China.

Industry Context

Bio-Techne operates in the life sciences and diagnostics industry, a sector characterized by rapid innovation, significant R&D investment, and a complex regulatory landscape. The industry is driven by advancements in areas like genomics, proteomics, and cell and gene therapy. Key trends include the increasing demand for personalized medicine, the growth of bioprocessing solutions to support novel therapeutics, and the consolidation of smaller players by larger entities seeking to broaden their portfolios.

Regulatory Implications

As a life sciences company, Bio-Techne is subject to stringent regulations from bodies like the FDA and international equivalents, impacting product development, manufacturing, and marketing. Compliance with data privacy laws (e.g., GDPR, CCPA) is also critical, especially concerning patient data used in diagnostic tools. Changes in healthcare policy or reimbursement rates can also significantly affect demand for its products and services.

What Investors Should Do

  1. Review executive compensation details and rationale for pay-for-performance metrics.
  2. Assess the impact of strategic divestitures and new product introductions on future growth and margins.
  3. Monitor the company's response to market challenges, including biotech funding constraints and macroeconomic conditions in China.

Key Dates

  • 2025-10-30: Annual Meeting of Shareholders — Shareholders vote on key company matters, including director elections and executive compensation approval.
  • 2025-09-05: Record Date for Annual Meeting — Establishes the shareholders eligible to vote at the annual meeting.
  • 2025-02-01: Appointment of Dr. Amy Herr to the Board of Directors — Represents board refreshment and addition of expertise, replacing a long-serving member.
  • 2025-01-01: Effective Date for 100% Cap on rTSR metric — Demonstrates responsiveness to shareholder feedback on executive compensation design for fiscal year 2025.

Glossary

rTSR
Relative Total Shareholder Return. A metric used to compare a company's stock performance against a peer group. (It is a component of the executive compensation plan, used to align executive pay with long-term shareholder value creation relative to competitors.)
DEF 14A
Definitive Proxy Statement. A filing with the SEC that provides detailed information about matters to be voted on at a shareholder meeting. (This document contains crucial information about executive compensation, board structure, and shareholder proposals for Bio-Techne Corp.)
GAAP Earnings Per Diluted Share
Earnings per share calculated according to Generally Accepted Accounting Principles, reflecting the profit allocated to each outstanding share of common stock. (Provides a standardized measure of profitability, which decreased significantly in FY2025 compared to FY2024.)
Adjusted EPS
Earnings per share adjusted for certain non-recurring or non-operational items, providing a view of ongoing operational profitability. (Increased in FY2025, indicating improved underlying business performance despite GAAP decreases.)
Organic Growth
Revenue growth that excludes the impact of acquisitions, divestitures, and currency fluctuations. (Indicates the company's core business performance, which was 5% in FY2025 despite challenging market conditions.)
Adjusted Operating Margin
Operating margin adjusted for certain items, reflecting the profitability of the company's core operations. (Slightly decreased in FY2025, influenced by compensation accruals and product mix, highlighting a key area for management focus.)

Year-Over-Year Comparison

In fiscal year 2025, Bio-Techne reported total revenue of $1.2196 billion, achieving 5% organic growth, a slight deceleration from the prior year's performance. The adjusted operating margin saw a minor decrease to 31.6% from 32.1% in fiscal year 2024, attributed to increased incentive compensation accruals and an unfavorable product mix. While GAAP EPS declined significantly from $1.05 to $0.46, adjusted EPS improved to $1.92 from $1.77, indicating underlying operational strength. Shareholder returns remained robust, with $326 million distributed via dividends and buybacks, compared to the prior year's undisclosed total. No new significant risk factors were highlighted in the provided text compared to the previous filing, though the company continues to navigate market dynamics.

Filing Stats: 4,246 words · 17 min read · ~14 pages · Grade level 14.5 · Accepted 2025-09-19 07:00:41

Key Financial Figures

  • $326M — 2025 5% organic growth for the year $326M capital returned to our shareholders
  • $1.2 billion — fiscal year, with our revenue exceeding $1.2 billion. We delivered these results with a cont
  • $0 — r. GAAP earnings per diluted share were $0.46, while adjusted EPS was $1.92 per di
  • $1.92 — hare were $0.46, while adjusted EPS was $1.92 per diluted share. We also returned $32
  • $326 million — .92 per diluted share. We also returned $326 million in capital to our shareholders through
  • $50 million — in capital to our shareholders through $50 million in dividends and $276 million in share
  • $276 million — rs through $50 million in dividends and $276 million in share buybacks. Our innovation was
  • $1,219.6M — s, and molecular diagnostic products. $1,219.6M Total Company Revenue (GAAP Revenue)
  • $45 million — o-Techne's participation in Spear Bio's $45 million Series A funding round in 2024. We si
  • $73.4M — ss spatial biology instrument, COMET. $73.4M $383.6M $0.46 per diluted share $
  • $383.6M — l biology instrument, COMET. $73.4M $383.6M $0.46 per diluted share $1.92 per d
  • $0.46 — instrument, COMET. $73.4M $383.6M $0.46 per diluted share $1.92 per diluted s
  • $1.05 — ome GAAP earnings per share , versus $1.05 per diluted share last fiscal year. A
  • $1.77 — cal year. Adjusted EPS , compared to $1.77 per diluted share in fiscal year 2024

Filing Documents

Executive Compensation

Executive Compensation 40 A Message from Our Compensation Committee 41 Key Highlights of Fiscal Year 2025 42 Compensation Discussion and Analysis 42 Executive Summary 42 Compensation Philosophy and Objectives 45 Our Process for Establishing

Executive Compensation

Executive Compensation 46 Compensation Policies and Practices 55 Compensation Committee Report on Executive Compensation 57 Additional Compensation Disclosures 58 Proposal 4: Ratification of Appointment of KPMG LLP as the Company's Independent Registered Public Accounting Firm for Fiscal Year 2026 69 Share Information 72 Equity Compensation Plan Information 72 Principal Shareholders 72 Management Shareholdings 73 Information About the Annual Meeting 75 Appendix A A-1 | 2025 Proxy Statement 4 Back to Contents Proxy Statement Summary This section highlights selected information contained in this Proxy Statement. Please read the full Proxy Statement carefully before voting. 2025 Annual Meeting of Shareholders Date and Time October 30, 2025 8:00 a.m. (Central Time) Place Webcast at www.virtualshareholdermeeting/TECH2025 Record Date September 5, 2025 Voting Holders of Bio-Techne common stock can vote in one of four ways: online at www.proxyvote.com, by telephone at 1-800-690-6903, by completing and returning a proxy card, or on the Annual Meeting web page. For more information, see "Information About the Annual Meeting." Our Board of Directors is asking you to take the following actions at the Annual Shareholder Meeting: Item Your Board's Recommendation Page 1. Set the number of members of the Board of Directors at nine FOR 14 2. Elect the nine individuals nominated to be directors of the Company FOR 14 3. Approve, on an advisory basis, the compensation of our executive officers FOR 39 4. Ratify the appointment of KPMG, LLP as the Company's independent registered public accounting firm for the 2026 fiscal year FOR 69 What's New? Our Nominations and Governance Committee selected, and our Board appointed, Dr. Amy Herr to join the Board of Directors on February 1, 2025. Dr. Herr was also appointed as a member of the Science and Technology Committee. Dr. Herr replaces Dr. Ro

Executive Compensation Highlights

Executive Compensation Highlights Our executive compensation program is designed to motivate our talented management team by rewarding progress towards Bio-Techne's longer-term strategies and the successful execution of our short-term business plans. Accordingly, we anchor our executive pay program on a foundation of pay-for-performance, and aligned to the financial goals we believe are most effective at driving long-term shareholder value creation so that executives and long-term shareholders alike can benefit from Bio-Techne's success and growth. In fiscal year 2025, the Compensation Committee continued to refine the newly added relative total shareholder return (rTSR) metric, which constitutes 25% of our three-year performance-vesting incentive vehicle for executive officers. After implementing this metric in fiscal year 2024 and considering shareholder perspectives, the Compensation Committee imposed a 100% cap on the rTSR payout in instances where Bio-Techne's TSR is negative during the three-year measurement period. With this modification, the Compensation Committee sought to achieve greater alignment between executive compensation and shareholder experience while still ensuring recognition for performance that surpasses that of our peers. Additionally, the Compensation Committee revisited its process and timeline for evaluating the performance of executive officers and setting executive officer compensation, as well as its executive compensation philosophy and approach to risk management with respect to executive compensation. See the Section on Our Process for Establishing Executive Compensation within the Compensation Discussion and Analysis on page 46. Last, the Compensation Committee gave thorough and rigorous consideration to shareholder suggestions that the Company include additional, differentiated metrics in our annual incentive bonus and three-year performance-based compensation programs. The Committee evaluated potential annual bonus metrics of

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.